Cancer – ADVL1514: Phase 1 Study of ABI-009 in Pediatric Patients with Recurrent or Refractory Solid Tumors
Condition or Therapy:
CNS and Solid Tumors
What is the goal of this study?
The goal of this study is is estimate the maximum tolerated dose and/or the recommended phase 2 dose of ABI-009 administered as an intravenous infusion over 30 minutes on days 1 and 8 of a 21-day cycle, in combination with temozolomide and irinotecan hydrochloride (irinotecan) in pediatric patients with recurrent or refractory solid tumors, including central nervous system tumors.
Who can join the study?
This study might be a good fit for children and young adults who:
- Are between 12 months and 21 years ol
- Have a BSA of over 0.2 m^2 and must have a recurrent or refractory solid tumor, including CNS tumors.
What will happen if my child takes part in this study?
You can read more about this study on clinicaltrials.gov.
Who can I contact for more information?
To learn more, call 206.987.2106 or send us an email.